Impact of new treatment options for hepatitis C virus infection in liver transplantation

Table 4 Outcome of pre-transplant hepatitis C virus therapy in studies with different regimens

Ref.	Population	n	Treatment regimen	Outcome	Adverse effects
Everson et al[74], 2005	63% decompensated cirrhosis (MELD 11 ± 3.7)	124	IFN (5 MU 3/wk) or Peg-IFN (0.75 μg/kg per week)/RBV (600 mg/d escalated)	SVR 13% (G1), 50% (other genotypes) 53% relapse 29% completed course	13% discontinuations and SAE (2 deaths)
Crippin et al[75], 2002	LT waiting list	15	IFN (3 MU 3/wk or 1 MU/d) ± RBV 400 bid	SVR 33%	1.3 SAE/patient (one death)
Forns et al[145], 2003	LT waiting list	30	IFN (3 MU/d)/RBV 800 mg/d	SVR 20% (3 relapse after LT)	63% dose reduction
Thomas et al[76], 2003	LT waiting list	21	IFN (5 MU/d)	SVR 20% (8 relapse after LT)	No SAE
Carrión et al[78], 2009	LT waiting list	51	Peg-IFN/RBV	SVR 20%	39% bacterial infections
Everson et al[79], 2013	LT waiting list	59	Peg-IFN/RBV (from 0.75 μg/kg per week and 600 mg/d escalated)	SVR12 22% (G 1-4), 29% (G 2-3), 50% if > 16 wk	68% (2.7 SAE/patient)
Verna et al[11], 2015	LT waiting list	29	PI-based triple therapy (93% TVR, 7% BOC)	SVR 52%	31% SAE; one death 28% hospitalizations
Curry et al[81], 2015	LT waiting list for HCC (CTP < 7)	43	Sofosbuvir 400/d plus RBV 1000-1200 up to 48 wk	SVR pre-LT maintained in 69% LT	18% SAE 2 discontinuation
Charlton et al[82], 2015	Decompensated cirrhosis	108	LDV/SOF/RBV (600 mg/d escalating) 12 vs 24 wk	SVR 87% vs 89%, CTP B 87% vs 89%, CTP C 86% vs 87%	26% SAE 3 discontinuation
Poordad et al[85], 2015	Advanced cirrhosis (70% CTP B-C)	60	DCV/SOF/RBV 12 wk	SVR 83%, CTP A 91%, CTP B 92%, CTP C 50%	No SAE

LT: Liver transplant; HCC: Hepatocellular carcinoma; CTP: Child-Turcotte-Pugh; IFN: Interferon; Peg-IFN: Pegylated interferon; RBV: Ribavirin; SVR: Sustained virological response; G: Genotype; SAE: Serious adverse effects; MELD: Model for End-Stage Liver Disease; PI: Protease inhibitor; TVR: Telaprevir; BOC: Boceprevir; LDV: Ledipasvir; SOF: Sofosbuvir; DCV: Daclatasvir.